Salute e Benessere

Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025

DUBLIN, May 29, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present new research related to ALKS 2680 at SLEEP 2025, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 8-11, 2025 in Seattle. ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in phase 2 development as a once-daily treatment for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). DUBLIN...
PR Newswire
29/05/2025

Brainomix Driving Treatment Decisions in Stroke: New Studies Presented at…

Dr Albert Yoo (Texas Stroke Institute) presented results from a research collaboration between Brainomix and the TESLA Trial team, whose randomized study was originally published in JAMA in September 2024. In this new analysis of the trial data, Brainomix 360 Stroke was used to estimate the ischemic core volume and degree of hypoattenuation on the non-contrast CT (NCCT) scans taken upon admission for the 276 large vessel occlusion (LVO) patients included in the original study. The results showed…
PR Newswire
29/05/2025

AI Meets Audit Powerhouse: Qualifyze Launches Quality Insights Platform to Help…

Supply Chains on the Brink: Why Pharma Can't Afford to Wait Ensuring timely availability of medicines has become one of the toughest challenges in pharma today. While current tariffs on US imports have spared the pharma sector for now, ripple effects across the global economy are here to stay and are intensifying cost pressure. Furthermore, the tightening of regulatory frameworks, growing geopolitical tensions, and climate-related disruptions make the need for agile, proactive site...
PR Newswire
29/05/2025

BMC Medical Highlights Global Innovation in Respiratory Care at ARTP and…

Later in the month, BMC made a high-profile appearance at HOSPITALAR 2025 (May 20–23), Latin America's premier medical trade show. At the event, BMC Medical introduced a comprehensive lineup of respiratory innovations, including the M1 Mini, G3 BPAP series, HFNC devices, RV series ventilators and PAP Link Digital Health solution. Later in the month, BMC made a high-profile appearance at HOSPITALAR 2025 (May 20–23),Latin America'spremier medical trade show. At the event, BMC Medical...
PR Newswire
29/05/2025

Drug Discovery Market Size, Share, CAGR, Growth - 2034

Cervicorn Consulting
29/05/2025

Contract Development And Manufacturing Organization Market Tends 2025-2034

Cervicorn Consulting
29/05/2025

Biologics Market Share & CAGR 2025-2034

Cervicorn Consulting
29/05/2025

Bionical Emas and Pharma Resources Announce Exclusive Global Clinical Trial…

This collaboration strengthens Bionical Emas' position as a trusted supply partner and highlights its continued success in forging impactful global alliances. As the sole distributor, Bionical Emas will streamline access to Pharma Resources' oncology portfolio for pharmaceutical companies, CROs, and clinical trial providers worldwide. This collaboration strengthens Bionical Emas' position as a trusted supply partner and highlights its continued success in forging impactful global alliances...
PR Newswire
29/05/2025

How to Find a Skincare Manufacturer

Start with a Clear Product Vision Start with a Clear Product Vision Before looking for a manufacturer, it's important to know exactly what kind of skincare product you want to create. This includes choosing between private label, white label, or custom formulations. Ridgepole works with all three types, helping brands at every stage of development. Brands should also define their niche—whether that's organic skincare, acne treatment, or luxury beauty. Having a clear direction will...
PR Newswire
29/05/2025

Halia Therapeutics CEO Dr. David Bearss to Deliver Keynote Address at Med…

The keynote will explore how insights from resilient individuals—those who remain disease-free despite genetic risk—are reshaping therapeutic development. Halia's research, grounded in population-scale genomic data, is enabling breakthrough treatments for inflammatory and neurodegenerative diseases. The keynote will explore how insights from resilient individuals—those who remain disease-free despite genetic risk—are reshaping therapeutic development. Halia's research, grounded in...
PR Newswire
29/05/2025

The 137th Canton Fair: Design Innovation Forum Unveils Fashion Trend Report for…

Despite global markets uncertainties, the fashion industry continues to show resilience. The forum addressed how "small-batch, multi-style, and agile" production is becoming the industry norm. Consumer demand is shifting toward personalized, sustainable, and functional fashion, prompting the industry to move from inspiration-driven creation to data-informed design. Despite global markets uncertainties, the fashion industry continues to show resilience. The forum addressed how…
PR Newswire
29/05/2025

Merck's WELIREG Entry Brings New Momentum to Pheochromocytomas and…

Sympathetic tumors often secrete large quantities of catecholamines and are found in the adrenal medulla in about 80% of cases. The remaining 20% are extra-adrenal, typically located along the prevertebral and paravertebral sympathetic ganglia in the chest, abdomen, or pelvis. In 2024, there were 4,900 incident PCPG cases across the 7MM, with numbers expected to rise in the coming years. Sympathetic tumors often secrete large quantities of catecholamines and are found in the adrenal medulla…
PR Newswire
28/05/2025

Nyxoah to Present at the Jefferies Global Healthcare Conference

Nyxoah to Present at the Jefferies Global Healthcare ConferenceMont-Saint-Guibert, Belgium – May 28, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies Global Healthcare Conference, which takes place June 3 – 5, 2025 in New York.Olivier Taelman, Nyxoah's...
Nasdaq GlobeNewswire
28/05/2025

Innocan Pharma Announces First Quarter 2025 Financial Results with Continued…

First Quarter 2025 Financial Highlights First Quarter 2025 Financial Highlights Corporate Highlights and Business Update Management Comments Iris Bincovich, CEO of Innocan Pharma, commented:"We are very pleased with our strong start to 2025, marked by solid results in the first quarter. This positive momentum reflects the dedication and excellence of our team. We continued to deliver meaningful, customer-centric innovation while maintaining a disciplined approach to...
PR Newswire
28/05/2025

Brand Licensing Market to Reach USD 470.55 Billion by 2030, Driven by Growth in…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-10C9173/Global_Brand_Licensing_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-10C9173/Global_Brand_Licensing_Market Major Factors Driving the Growth of Brand Licensing Market: The brand licensing market continues to evolve as companies look for innovative ways to extend brand equity and reach new consumer bases. Licensing offers a scalable, low-risk method to enter...
PR Newswire
28/05/2025

Pharmaceutical Lab Equipment Market to Hit USD 15.59 Billion by 2031, Driven by…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-32T9116/Global_Pharmaceutical_Lab_Equipment_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-32T9116/Global_Pharmaceutical_Lab_Equipment_Market Major Factors Driving the Growth of Pharmaceutical Lab Equipment Market: The pharmaceutical lab equipment market is undergoing robust growth due to heightened R&D activities, regulatory pressures, and advancements in drug...
PR Newswire
28/05/2025

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II…

Leuven, BELGIUM – May 28, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a transparency notification on May 27, 2025, from Atlas Special…
Actusnews Wire
28/05/2025

Compression Therapy Market worth US$5.9 billion by 2030 with 5.5% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=146548022 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=146548022 Browse in-depth TOC on "Compression Therapy Market" 400 - Tables 100 - Figures 400 - Pages By Based on Application,the varicose veins segment is the leading segment of the compression therapy market due to its direct link to the rising prevalence of this condition, especially among aging...
PR Newswire
28/05/2025

myTomorrows Launches Expanded Access Management SaaS Platform to Empower…

When no satisfactory treatments are available, EA programs provide critical pathways for physicians treating patients with serious or life-threatening conditions. Yet, navigating the regulatory complexity, documentation, and operational workflows of these programs can be highly burdensome, often resulting in prolonged treatment access and missed opportunities to collect valuable real-world data. When no satisfactory treatments are available, EA programs provide critical pathways for…
PR Newswire
28/05/2025

Metabolon's Untargeted Metabolomics Services Used for Landmark Study Linking a…

Globally, attention-deficit/hyperactivity disorder (ADHD) affects approximately 5–7% of children and adolescents and 2–5% of adults, with variations in prevalence influenced by regional differences in diagnostic practices. Autism spectrum disorder (ASD) has an estimated global prevalence of about 1–2% (around 1 in 100 children), although some recent studies suggest rates up to 2.3%. Boys are diagnosed with autism roughly four times more frequently than girls. Globally,...
PR Newswire
28/05/2025

CPHI & PMEC China Sees Surge in International Attendance as Global Pharma Trade…

The event's surge in global interest coincides with easing trade tariffs, improved pharmaceutical valuations, and increased capital expenditure across the sector. International executives are attending in record numbers, seeking new ingredient suppliers and equipment providers in China's robust manufacturing ecosystem. The event's surge in global interest coincides with easing trade tariffs, improved pharmaceutical valuations, and increased capital expenditure across the sector. International...
PR Newswire
28/05/2025

IM Cannabis Announces Plans to Voluntarily Delist from the Canadian Securities…

The Company is grateful to the CSE for providing its initial opportunity to access public markets. It is expected, subject to approval from the CSE, that the close of business on Monday, June 2, 2025, will be the final trading day for IMC on the CSE. The Company is grateful to the CSE for providing its initial opportunity to access public markets. It is expected, subject to approval from the CSE, that the close of business onMonday, June 2, 2025, will be the final trading day for IMC on the...
PR Newswire
28/05/2025

Phenomenex Unveils New LC Column Connector for Optimized LC and Low-Flow…

"Laboratories conducting LC analysis may face challenges in their results caused by unreliable column connections," says Maryam Sayeed, Product Manager at Phenomenex. "SecurityLink ET provides a reliable solution, for consistent LC column connectivity to LC systems minimizing the risk of system downtime and reinforcing confidence in laboratory workflows." "Laboratories conducting LC analysis may face challenges in their results caused by unreliable column…
PR Newswire
28/05/2025

Waters Introduces BioResolve Protein A Affinity Columns to Accelerate Antibody…

"Today's launch of the BioResolve Protein A Affinity Columns will help to bring lifesaving therapies to patients, faster. One of the main bottlenecks in the development of biotherapeutics like monoclonal antibodies is the time required to identify and optimize a suitable cell line for antibody production," said Dr. Udit Batra, President and Chief Executive Officer, Waters Corporation. "We have solved for this by designing a novel, highly efficient particle with an immobilized…
PR Newswire
28/05/2025
Altri  Comunicati